Latest Interviews
Showing 16–20 of 20 transcripts.
Clear all filters- The Economist14 min
How gene editing could reduce the cost of cosmetics
Sunil Chandran, Jason Kelly, Alok Jha
Biotech firms like Amaris and Ginkgo are rapidly scaling the production of cosmetic ingredients through synthetic biology, currently supplying the majority of the global squalane market while securing contracts to engineer novel scents and fragrances. This shift replaces unsustainable extraction methods that endanger shark populations and deplete natural resources, offering companies the potential for 50% cost savings alongside regulatory advantages in the US and EU. Beyond ingredient sourcing, the sector is increasingly leveraging engineered microbes to address industry-wide waste challenges, such as breaking down the 120 billion units of single-use packaging generated annually.
- The Economist10 min
Alien life: are we about to find it?
Driven by a decade of technological advancement, the scientific community is shifting from sci-fi speculation to rigorous analysis with the James Webb Space Telescope and upcoming 40-meter ground-based observatories poised to detect biosignatures like oxygen on Earth-like exoplanets. Despite the light-lag constraint making intelligent technosignatures unlikely to be verified soon, researchers are prioritizing the identification of liquid water and biological markers on targets such as Teegarden B. Experts project that these initiatives will either confirm the existence of extraterrestrial life within ten years or fundamentally alter our understanding of life's rarity in the universe.
- The Economist7 min
Covid-19: Can vaccines keep up with variants?
Driven by the Delta variant and potential mutations within immune-suppressed hosts, the pandemic persists as unchecked global transmission threatens to create vaccine-evading "omega" variants. Experts warn that while current vaccines remain effective against severe outcomes, the primary risk lies in uncontrolled spread leading to higher absolute death tolls and future immune evasion. To prevent this nightmare scenario, scientists advocate for proactive surveillance at human-animal interfaces and the development of rapid variant-specific vaccines alongside stricter laboratory and environmental security protocols.
- The Economist12 min
Covid-19: more questions about coronavirus, answered
Ed Carr, Alok Jha, Edward Carr
Policymakers and economic analysts are addressing the severe trade-off between strict disease containment and deepening economic contraction, with US Treasury Secretary Steve Mnuchin warning that unemployment could reach 20% without intervention. The event evaluates the likely L-shaped recession trajectory while examining how global aid, healthcare disparities, and the virus's seasonal mutation patterns will shape long-term recovery. Ultimately, the discussion emphasizes the necessity of international cooperation to restore scientific trust and accelerate vaccine development within an 18-to-24-month window despite rising nationalistic trends.
- The Economist17 min
Covid-19: your questions about coronavirus, answered
Ed Carr, Alok Jha, Edward Carr
A unique global crisis combining simultaneous supply and demand shocks has erased $23 trillion in market value while disproportionately devastating developing nations and specific industries like aviation and hospitality. Political risks are rising as states consolidate emergency powers in countries such as Hungary and China, even as health systems struggle with limited testing data and varying mortality rates. Although vaccines remain the primary long-term solution, interim strategies are shifting toward oscillating lockdowns, targeted antibody testing, and urgent clinical trials involving existing antiviral drugs.